Introduction:
Aytu BioPharma and AMT Manufacturing Solutions have recently reached an agreement regarding the subleasing of a portion of Aytu's manufacturing facility located in Grand Prairie, Texas, in the United States.
Features:
This collaborative agreement allows AMT to utilize a section of Aytu's FDA and DEA-approved pharmaceutical production plant.
The sublease encompasses an area of 22,909 square feet, which accounts for more than 30% of Aytu's existing production facility.
As part of the agreement, the sublease will be expanded to encompass the remaining manufacturing space, totaling 77,112 square feet.
The expanded sublease is expected to come into effect on April 1, 2024, and will conclude no later than December 31, 2024. During this period, AMT will have access to the additional manufacturing facility provided by Aytu.
Specifications:
Name | Aytu BioPharma |
Type | Expansion |
Year | 2024 |
